Shanghai Henlius Biotech (HKG:2696) obtained approval for a phase 1 clinical trial of HLX48 for injection from Australia's relevant regulatory authorities, according to a Wednesday Hong Kong bourse filing.
The drug will be tested for the treatment of advanced/metastatic solid tumors.